![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 25, 22215-22221, June 21, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Institut de Génétique Humaine, CNRS UPR 1142, 141 rue de la Cardonille, 34396 Montpellier cedex 5, France
Received for publication, February 26, 2002, and in revised form, April 8, 2002
The human immunodeficiency virus type-1
trans-activator Tat is a transcription factor that
activates the HIV-1 promoter through binding to the
trans-activation-responsive region (TAR) localized at the
5'-end of all viral transcripts. We and others have recently shown that
Tat is directly acetylated at lysine 28, within the activation domain,
and lysine 50, in the TAR RNA binding domain, by Tat-associated histone
acetyltransferases p300, p300/CBP-associating factor, and hGCN5.
Here, we show that mutation of acetyl-acceptor lysines to arginine or
glutamine affects virus replication. Interestingly, mutation of lysine
28 and lysine 50 differentially affected Tat trans-activation of integrated versus
nonintegrated long terminal repeat. Our results highlight the
importance of lysine 28 and lysine 50 of Tat in virus replication and
Tat-mediated trans-activation.
Human immunodeficiency virus type-1
(HIV-1)1 Tat is a regulatory
protein encoded by two exons localized on either side of the env gene. Tat is a multifunctional protein, absolutely
required for virus replication and AIDS progression. Besides its
primary function as the viral transcription factor, Tat has been
proposed to be required for efficient reverse transcription (1). Tat is
secreted from infected cells (2, 3), whereupon it binds to neighboring
cells through electrostatic interactions, chemokine receptors (4), or
cell surface integrins (5). Extracellular Tat is a cellular toxin that
increases the efficiency of virus dissemination and reduces antiviral
immunity to promote HIV-1 disease (6). Cells treated with Tat show
increased expression of chemokine receptors (7, 8), decreased
proliferation (9, 10), and apoptosis of bystander cells (11, 12).
Furthermore, Tat has been shown to have chemokine-like properties that
may serve to recruit chemokine receptor-expressing
monocytes/macrophages toward HIV-producing cells and facilitate
infection (3-5). Finally, extracellular HIV-1 Tat protein has been
shown to selectively inhibit the entry and replication of T-cell tropic
X4, but not macrophage-tropic R5, virus in peripheral blood mononuclear
cells, which has been proposed as a mechanism to select against X4
viruses, thereby influencing the early course of HIV-1 disease
(13).
The primary function attributed to Tat is its role in HIV-1 promoter
activation. Tat is an atypical transcriptional activator that functions
through binding, not to DNA, but to a short leader RNA,
trans-activation responsive region (TAR) localized at the 5'
termini of all viral transcripts (14-16). Interaction between Tat and
TAR is necessary for HIV-1 transcription both in
vivo (17, 18) and in vitro (19, 20).
Tat transcriptional activity on the HIV-1 promoter is tightly regulated
by cellular factors (reviewed in Ref. 21): Tat-associated-kinases
(22-24) and Tat-associated histone acetyltransferases (25-28).
Tat-associated kinase was identified as the kinase subunit of the
positive transcription elongation factor b (29-33). Positive
transcription elongation factor b is composed of a regulatory subunit,
cyclin T1, and a catalytic subunit, CDK9, which phosphorylates the
carboxyl-terminal domain of the large subunit of RNA polymerase II (32,
34). Hyperphosphorylation of the RNA polymerase II carboxyl-terminal
domain leads to productive elongation of transcription (24, 32, 33,
35-37). Tat interacts with cyclin T1 to recruit positive transcription
elongation factor b to the HIV-1 TAR element and to stimulate
elongation of transcripts originating from the viral long terminal
repeat (LTR) (32, 33). The other class of Tat co-activators,
Tat-associated histone acetyltransferases, are composed of p300/CBP,
p300/CBP-associating factor (PCAF) (25-27), and hGCN5 (28).
Tat-associated histone acetyltransferases induce the activation of
chromatinized HIV-1 LTRs (26, 27), presumably through acetylation of
histones. Tat may also use the cellular acetylation pathway to control
the expression of various cellular genes (38, 39). We and others have
recently shown that Tat-associated histone acetyltransferases also
directly acetylate the Tat protein in two different domains. Whereas
p300 and hGCN5 acetylate lysine 50 within the RNA binding domain (28,
40-42), PCAF acetylates lysine 28 in the activation domain (40). Thus,
this novel post-translational modification of Tat was found to govern
two essential interactions necessary for HIV-1 transcription: binding
of Tat to TAR and to positive transcription elongation factor b.
In the present work, we analyzed the role of Tat acetyl- acceptor
lysines in virus replication. We show that mutation of lysine 28 and
lysine 50 to either arginine or glutamine severely affected the
replication of HIV-1 in a T-cell line. Additionally, the effect of
Lys28 and Lys50 mutation on Tat
trans-activation was dependent on the promoter context
(integrated versus nonintegrated LTR). Our results highlight the importance of lysine 28 and lysine 50 of Tat in virus replication and the mechanism of Tat-mediated trans-activation.
Plasmid Constructs--
pLTR-luc wild-type has been described
(40). A FLAG sequence was introduced in the COOH terminus of pTat wild
type, which was used as a template for mutagenesis. pTat-K28R,
pTat-K28Q, pTat-K29R, pTat-K50R, and pTat-K50Q were generated by the
site-directed mutagenesis method using the QuikChange kit (Stratagene).
Mutated clones were fully sequenced after identification. All proviral constructions were derived from the pNL4-3 infectious molecular clone
(43). pNL4-3 Tat( Transfection and Infection--
CEM cells were grown in RPMI
1640 medium (Invitrogen) supplemented with 10% FBS and
antibiotics. 293, HeLa, and HeLa P4 cells, that contain the
lacZ gene under control of the integrated HIV-1 LTR (46),
were propagated in Dulbecco's modified Eagle's medium with 10% fetal
bovine serum and transfected using calcium phosphate as described (40).
Virus stocks were produced by transfection of 293 cells. Transfected
cell supernatants were harvested at 48 h post-transfection and
passed through 0.45-µm pore size filters. Viruses, normalized for
reverse transcriptase (RT) activity, were used to infect CEM and HeLa
P4 cells. Briefly, cells were incubated with virus for 2 h at
37 °C, washed, and resuspended in fresh medium. Virus
production was monitored by RT assay of culture supernatants every 3 days.
RT and Reporter Assays--
To measure RT activity, 10 µl of
cell culture supernatants was mixed with 25 µl of RT buffer (60 mM Tris-HCl (pH 8), 75 mM KCl, 5 mM
MgCl2, 0.1% IGEPAL CA-630, 1.04 mM EDTA, 5 µg/ml poly(A), 0.16 µg/ml oligo(dT), 40 mM
dithiothreitol, and 10 µCi/ml [ In Vitro TAR/Tat Binding Assay--
Wild-type and mutant Tat
proteins were translated in vitro in a coupled
transcription-translation rabbit reticulocyte lysate system (Promega)
in the presence of [35S]methionine according to the
manufacturer's protocol. Synthetic biotinylated TAR RNA (2 µg) was
immobilized on streptavidin-agarose beads and incubated with
translated proteins for 2 h at 4 °C. The complex was then
washed, resolved by SDS-PAGE, and analyzed by autoradiography.
Immunological Techniques and Western Blot Analysis--
HeLa
cells were transfected with the indicated plasmids. At 24 h
post-transfection, cells were washed twice in phosphate-buffered saline
and lysed in ice-cold lysis buffer (50 mM Tris-HCl (pH 8),
120 mM NaCl, 5 mM EDTA, 0.5% IGEPAL CA-630, 1 mM dithiothreitol, and protease inhibitor mixture). The
cell lysates were clarified by centrifugation at 15,300 × g for 5 min, and supernatants were subjected to
immunoprecipitation with the indicated antibody following a preclearing
step. Immunoprecipitates were then washed three times with lysis buffer
and resolved by SDS-PAGE. Proteins were transferred to polyvinylidene
difluoride membrane using semidry blotting (Bio-Rad). Membranes were
incubated with the primary antibody overnight at 4 °C, washed, and
incubated for 1 h with the appropriate secondary antibody
(Amersham Pharmacia Biotech). Proteins were visualized by
chemiluminescence (Amersham Biosciences) according to the
manufacturer's protocol. For immunofluorescence, HeLa cells were
transfected with plasmids expressing FLAG-tagged Tat wild type or
mutants. Cells were fixed 24 h after transfection with 4%
paraformaldehyde for 10 min at room temperature. The cells were
then washed and permeabilized in 1× phosphate-buffered saline containing 5% fetal calf serum and 0.1% Triton X-100 for 10 min at
room temperature. Cells were stained with anti-FLAG antibody followed
by incubation with Texas Red-conjugated anti-mouse antibody.
Mutation of Tat Acetyl-acceptor Lysines Affects HIV-1
Replication--
HIV-1 Tat is essential for virus replication and is a
potent trans-activator of viral gene expression (20). We
have recently shown that Tat lysine 28, within the activation domain,
and lysine 50, within the RNA binding domain, are targeted for
acetylation by PCAF and p300, respectively. Mutation of acetyl-acceptor
residues Lys28 and Lys50 to alanine reduces
Tat-mediated trans-activation of the HIV-1 promoter in
transient transfection assays (40). Previous analysis has shown a
discordance between residues that are important for virus replication
and those important for trans-activation of a transiently
transfected reporter gene under the control of the HIV-1 LTR (47).
Thus, we investigated the role of Tat acetyl- acceptor lysines in HIV-1
replication. Lysine 28 and lysine 50 were mutated to either arginine or
glutamine. As a control, lysine 29 that is not acetylated was also
mutated to arginine. Using a previously described strategy (45), Tat
wild-type or mutants were introduced in the nef frame of
pNL4-3 Tat(
We then analyzed the replication of recombinant pNLT( Effect of Tat Acetyl-acceptor Lysines on Tat-mediated Activation of
Integrated and Nonintegrated LTR--
To assess how mutation of Tat
acetyl-acceptor lysines (Lys28 and Lys50)
affects virus replication, we analyzed their effect on Tat-mediated trans-activation of an integrated and nonintegrated HIV-1
LTR. HeLa P4 cells that contain the lacZ gene under the
control of the integrated HIV-1 LTR (46) were infected with recombinant pNLT viruses encoding either Tat wild-type or mutants.
We then analyzed the transcriptional activity of Tat wild-type and
mutants in transient transfection assays. HeLa cells were transfected
with an LTR luciferase reporter gene either alone or with Tat
expression plasmids as indicated (Fig. 2B). The
transcriptional activity of Tat K50Q and Tat K28Q was reduced (3- and
6.5-fold, respectively), while that of Tat K50R and Tat K29R was
comparable with Tat wild type. Interestingly, the transcriptional
activity of Tat K28R, which was reduced by 5-fold on an integrated LTR, was comparable with that of wild-type in transient transfection assays
(1.35-fold reduction). As previously shown, the transcriptional activity of the Tat K41A was significantly reduced (22, 23). Taken
together, the experiments shown in Fig. 2 suggest that the effect of
Tat acetyl-acceptor lysines on Tat-mediated trans-activation is dependent on the promoter context. These experiments
furthermore suggest that activation of an integrated
versus nonintegrated HIV-1 LTR by Tat may involve different mechanisms.
Tat trans-activation of the HIV-1 LTR minimally requires
TAR, positive transcription elongation factor b, and Tat-associated histone acetyltransferases. Thus, we analyzed the effect of Tat acetyl-acceptor mutants on the interaction between Tat and TAR, cyclin
T1, and PCAF. Fig. 3A shows
that Tat wild type, Tat K28Q, Tat K28R, Tat K29R, and Tat K50R interact
with TAR RNA. However, a weak interaction was observed between Tat K50Q
and TAR RNA. This finding suggests that the reduced
trans-activation function of Tat K50Q is probably due to a
loss of its interaction with TAR RNA.
Because the positive transcription elongation factor b complex is
required for Tat trans-activation, we investigated the role of lysine 28 and 50 in the interaction of Tat with cyclin T1. HeLa
cells were transfected with FLAG-tagged Tat wild type or mutants.
24 h after transfection, cell extracts were prepared and subjected
to immunoprecipitation using anti-FLAG antibody. Immunoprecipitates
were resolved on SDS-PAGE, and the presence of cyclin T1 was analyzed
by immunoblotting using anti-cyclin T1 antibody. Fig. 3B
shows that Tat wild-type and mutants were able to interact with cyclin
T1. Tat K28R interaction with cyclin T1 was less efficient than Tat
wild type (compare lanes 2 and 7). As
previously reported, the Tat K41A mutant failed to interact with cyclin
T1 (lane 3). We then analyzed the effect of human cyclin T1 on Tat-mediated trans-activation of the LTR in NIH
3T3 cells. As shown in Fig. 3C, human cyclin T1 enhanced Tat
trans-activation by 3.4-fold. Although Tat K28Q and Tat K50Q
were able to interact with cyclin T1, no synergistic activation of the
LTR was observed. Human cyclin T1 enhanced Tat K28R and Tat K50R
trans-activation by 2.3- and 1.9-fold, respectively. As
expected, human cyclin T1 had no effect on Tat K41A transcriptional
activity. These results suggest that binding of Tat to cyclin T1 is
required but not sufficient for optimal trans-activation of
the HIV-1 LTR.
Finally, because PCAF is known to assist Tat in activation of an
integrated LTR (27), we analyzed the effect of Tat acetyl- acceptor
lysines on the interaction between Tat and PCAF. Co-immunoprecipitation analysis showed that Tat wild type, Tat K50R, Tat K50Q, Tat K28Q, and
Tat K29R were able to immunoprecipitate PCAF (Fig. 3D).
However, Tat K41A and Tat K28R interacted weakly with PCAF. The
expression level of Tat wild type and mutants is shown in the
lower panel (Fig. 3D). This result may
explain why Tat K28R is competent for activating the LTR in a transient
transfection assay (Fig. 2B) but activates the integrated
LTR poorly (Fig. 2A).
Because Tat K28Q and Tat K50Q are transcriptionally incompetent yet
bind to cyclin T1 and PCAF, we asked whether these mutants, by
sequestering cyclin T1 and/or PCAF, are able to compete with Tat
wild-type for LTR trans-activation. Thus, HeLa P4 cells were transfected with either Tat wild type alone or together with Tat mutants, and Mutation of Tat Acetyl-acceptor Lysines Affects Its Subcellular
Localization--
Tat acetyl-acceptor lysines are localized to the
activation domain (Lys28) that mediates the
interaction between Tat and its co-activators and the RNA binding
domain (Lys50) that also serves as a nuclear localization
signal. Thus, we analyzed the effect of Lys50 and
Lys28 mutations on the subcellular localization of Tat by
immunofluorescence (Fig. 5). HeLa
cells were transfected with either FLAG-tagged Tat wild type or mutants
as indicated, and cells were stained with anti-FLAG antibody. Tat wild
type showed a characteristic pattern consisting of diffuse
nucleoplasmic fluorescence with intense nucleolar staining in 78% of
transfected cells as observed previously (48, 49), whereas only 22% of
transfected cells showed both nuclear and cytoplasmic staining. Tat
K50Q was found to localize to both cytoplasm and nucleus in 90% of
transfected cells. Tat K50R localized exclusively in the nucleus in
93% of transfected cells. Thus, the positive charge of
Lys50 plays an important role in dictating Tat
localization. Tat K29R showed a similar staining pattern to Tat
wild-type. Mutation of Lys28 to glutamine increased the
number of cells that showed both nuclear and cytoplasmic staining of
Tat to 44%. Interestingly, Tat K28R, Tat K28Q, and Tat K41A showed a
perinucleolar, instead of diffuse nucleolar, localization as seen for
the Tat wild type, Tat K50R, and Tat K29R. These results suggest that
Lys41 and acetyl-acceptors Lys28 and
Lys50 of Tat influence its subcellular localization.
The HIV-1 trans-activator Tat is absolutely required
for virus replication and plays a critical role in AIDS pathogenesis. In this report, we have analyzed the role of acetyl-acceptors Lys28 and Lys50 in virus replication and Tat
transcriptional activity. Thus, lysines 28 and 50 were mutated to
either arginine (to conserve the positive charge) or glutamine (to
neutralize the positive charge). By introducing these mutations in the
pNL4-3 Tat minus background, using a previously described strategy (45,
47), we show that acetyl-acceptor Lys28 and
Lys50 play a critical role in virus replication. Mutation
of Lys28 or Lys50 to glutamine results in
replication-incompetent virus and transcriptionally inactive Tat on
integrated and nonintegrated LTR. Interestingly, mutation of lysine 50 to arginine did not affect Tat-mediated trans-activation of
either integrated or nonintegrated LTR but led to a 4-day delay in
virus replication. Mutation of lysine 28 to arginine affected virus
replication and activation of an integrated LTR without affecting LTR
trans-activation in a transient transfection assay.
To investigate how mutation of Tat acetyl-acceptor lysines affects Tat
transcriptional activity, we analyzed the effect of these mutations on
Tat/TAR, Tat/cyclin T1, and Tat/PCAF interactions. Consistent with our
previous report (40), mutation of lysine 50 to glutamine reduced the
ability of Tat to bind TAR RNA without affecting its interaction with
cyclin T1 or PCAF. Moreover, Tat K50Q has an altered cellular
localization with nuclear and cytoplasmic staining in 90% of
transfected cells. Thus, the lack of binding of Tat K50Q to TAR RNA and
its abnormal cellular localization probably contribute to its inability
to support virus replication and trans-activation of the
LTR.
Tat K28R is able to interact with TAR and cyclin T1 but failed to
interact with PCAF, one of the histone acetyltransferases that has been
shown to assist Tat-mediated trans-activation of integrated
LTR (27). Previously, it has been shown that the two-exon form of Tat
activates an integrated LTR more efficiently than the Tat one-exon form
(50). In the context of chromatin, Tat also has to overcome the
chromatin repression exerted by the nucleosomal architecture of the
integrated provirus (51, 52). In this respect, Tat has been shown to
disrupt the repressive nucleosome 1 (nuc1) to activate the
transcription from integrated LTR (52). Thus, the inability of Tat K28R
to activate an integrated LTR and, consequently, the reduced
replication of viruses carrying this mutation may be due to the loss of
its interaction with PCAF. Taken together, these results suggest a
fundamental difference in the mechanism by which Tat
trans-activates an integrated versus nonintegrated LTR.
Mutation of Tat Lys28 to glutamine had no effect on
Tat/TAR, Tat/cyclin T1, and Tat/PCAF interaction. Despite this, Tat
K28Q was transcriptionally inactive on both integrated and
nonintegrated LTR. Tat K28Q showed an altered subcellular localization
with 44% of transfected cells stained in both cytoplasm and nucleus. The inability of Tat K28Q to activate the LTR and consequently to
support virus replication may be explained, at least in part, by its
altered subcellular localization. Additionally, K28Q mutation may
affect the interaction between Tat and other cellular factors involved
in trans-activation of the LTR and virus replication.
Mutation of Tat K50R did not affect its interaction with TAR, cyclin
T1, or PCAF. Tat K50R activated both integrated and nonintegrated LTRs
as efficiently as Tat wild type. However, K50R mutation delayed virus
replication by 4 days. Transcriptionally competent Tat mutants unable
to support optimal virus replication have been reported previously
(47). How could transcriptionally active Tat fail to support optimal
virus replication? Besides its primary function as a
trans-activator of the viral promoter, Tat has been shown to
have pleiotropic effects on cellular genes and metabolism (20). Tat is
a secreted protein that is taken up by neighboring cells (2, 3). It has
been shown that soluble Tat protein can activate noninfected cells,
thus preparing a favorable cellular environment for virus replication
(53). Soluble Tat is able to activate transcription factors, such as
NF- Accumulating evidence suggests that Tat may also be an important
virulence factor in vivo. Vaccination of nonhuman primates with Tat, either alone or in combination with other viral products, reduces virus replication (6, 57-61). Whereas native Tat protein is
cytotoxic, a modified Tat protein is considered an attractive target
for HIV vaccine development. Thus, identification of Tat mutants able
to compete with and inhibit wild-type Tat function will help to
engineer the optimal Tat protein vaccine candidate.
We thank members of the Benkirane and
Corbeau laboratories for helpful discussions, J. Demaille for
support, B. Reant for technical assistance, P. Charneau for HeLa P4
cells, and K. T. Jeang for pNL4-3 Tat( *
This work was supported by grants from the Agence
Nationale de Recherche sur le SIDA (ANRS) and Action Concerte
Initiative blanche (to M. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by an ANRS fellowship.
¶
Present address: Institut Cochin de Génétique
Moléculaire, INSERM U529, 24 rue du Faubourg Saint Jacques, 75014 Paris, France.
Published, JBC Papers in Press, April 15, 2002, DOI 10.1074/jbc.M201895200
The abbreviations used are:
HIV-1, human
immunodeficiency virus type 1;
TAR, trans-activation-responsive region;
LTR, long terminal
repeat;
PCAF, p300/CBP-associating factor;
RT, reverse
transcriptase.
Tat Acetyl-acceptor Lysines Are Important for Human
Immunodeficiency Virus Type-1 Replication*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) was generated by introducing two consecutive stop
codons at amino acids 11 and 12. The plasmid was designated pNLT(
).
To generate pNLT(
) that expresses wild-type or mutant Tat, wild-type
or mutated tat coding sequence was introduced into the
nef gene of pNLT(
) (44, 45). The resultant molecular genomes were designated pNLT, pNLT-K28Q, pNLT-K28R, pNLT-K29R, pNLT-K50Q, and pNLT-K50R.
-32P]dTTP (Amersham
Biosciences)). The reactions were incubated for 2 h at 37 °C,
and 10 µl was spotted onto a DEAE filter, washed three times in 2×
SCC, dried, and quantified using an Instant Imager (Packard). To assay
luciferase activity, transfected HeLa cells were lysed and assayed for
luciferase activity 48 h post-transfection, according to the
manufacturer's protocol (Promega).
-galactosidase activity was
measured in extracts of HeLa P4 cells 48 h post-transfection or
24 h postinfection, according to the manufacturer's protocol (Roche Molecular Biochemicals).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) in which the tat gene had been inactivated by
engineering two consecutive stop codons at amino acids 11 and 12 (Fig.
1A). The different constructs were used to transfect 293 cells, which express the adenoviral proteins E1A and E1B that strongly
activate HIV-1 LTR and complement the defect in gene expression in
viruses lacking Tat (45). Biochemical analysis of the resultant virions
was performed. Fig. 1B shows that expression of viral
proteins from recombinant genomes encoding wild-type or mutant Tat was
identical. Furthermore, FLAG-tagged wild-type and mutant Tat proteins
were readily detected in cells transfected with each of the respective
viral genomes (Fig. 1C). The reverse transcriptase
activity/p24 ratio was identical for all the molecular clones
engineered (Fig. 1D). Thus, the engineered recombinant
pNL4-3 molecular clones are competent for expression of the HIV-1
structural proteins with a normal RT/p24 ratio when transfected into
293 cells.
) encoding
wild-type or mutant Tat in a T-cell line. Viruses, produced from 293 cells transfected with pNLT or pNLT mutants, were normalized for RT
activity and used to infect CEM cells. Infected cells were monitored
for virus replication by measuring supernatant RT activity every 2 or 3 days over a period of 21 days. Tat wild-type and Tat K29R viruses
showed the same replication kinetics with an RT peak at day 13 postinfection (Fig.
1E).
However, the mutations K28R, K28Q, and K50Q imposed significant
replication defects. Tat K50R virus showed a 4-day delay to peak virus
production when compared with the recombinant Tat wild-type virus.
These results show that the acetyl-acceptor lysines within Tat play an
important role in virus replication.

View larger version (18K):
[in a new window]
Fig. 1.
Analysis of pNL4-3 Tat(
) viruses that
express wild-type or mutant Tat. A, construction of
pNL4-3 Tat(
) provirus engineered to express wild-type or mutant Tat.
The pNL4-3 molecular genome was used as a backbone to generate pNL4-3
Tat(
), hereafter referred to as pNLT(
), by the introduction of two
consecutive stop codons at amino acids 11 and 12. To generate pNLT(
)
that expresses wild-type or mutant Tat, wild-type or mutated
tat coding sequence was introduced into the nef
gene of pNLT(
). The resultant molecular genomes were designated pNLT,
pNLT-K28Q, pNLT-K28R, pNLT-K29R, pNLT-K50Q, and pNLT-K50R.
B, biochemical analysis of pNLT(
) viruses expressing
wild-type or mutant Tat. Western blot analysis was performed
with equal quantities of virions produced from 293 cells transfected with pNLT(
) expressing wild-type or
mutant Tat. HIV-1-specific proteins were detected using an
HIV-1-neutralizing serum. C, Tat is efficiently expressed
from recombinant pNLT(
) molecular genomes encoding wild-type or
mutant Tat. Extracts of cells transfected with the indicated molecular
genomes were analyzed by Western blotting using an anti-FLAG antibody.
D, RT activity and p24 antigen of viruses produced by
transfection of 293 cells with pNLT(
) expressing wild-type or mutant
Tat. Data are averages from at least three independent assays ± S.E. E, Tat acetyl-acceptor lysines affect virus
replication. Virus stocks obtained by transfection of 293 cells with
the indicated molecular genomes were normalized for RT activity and
used to infect CEM cells. RT activity in the cell supernatant was
monitored over time.
-Galactosidase activity was monitored 24 h after infection.
Fig. 2A shows that transcriptional activity of Tat K50Q, Tat K28R, and Tat K28Q on the
integrated LTR was severely reduced. Tat K50R transcriptional activity
was slightly (1.6-fold) higher than the wild type. Similar results were
obtained when the Tat-expressing constructs were transfected into HeLa
P4 cells (data not shown). Taken together, these results show a
correlation between the lack of transcriptional activity of Tat K28R,
K28Q, and Tat K50Q on an integrated LTR and their inability to support
virus replication. In contrast, the Tat K50R mutant, which showed
delayed replication kinetics, was found to have slightly enhanced
trans-activation.

View larger version (12K):
[in a new window]
Fig. 2.
Tat acetyl-acceptor Lys28 and
Lys50 are important for Tat-mediated
trans-activation of the HIV-1 LTR. A,
virus stocks obtained by transfection of 293 cells with the indicated
molecular genome were normalized for RT activity and used to infect
HeLa P4 cells. Cell extracts were assayed for
-galactosidase
activity 24 h postinfection. The results are presented as
histograms indicating the induction of the integrated LTR by the
indicated viruses with respect to the activity of cells infected with
supernatant alone, which was assigned a value of 1. Data are averages
from at least three independent assays ± S.E. B, HeLa
cells were co-transfected with 1 µg of pLTR-luc wild type
(Wt) and 0.1 µg of pRL-CMV either alone or together with
0.5 µg of plasmids expressing wild-type or mutated Tat as indicated.
The relative luciferase activity was calculated following normalization
for Renilla luciferase activity. Data are averages from at
least three independent assays ± S.E.

View larger version (32K):
[in a new window]
Fig. 3.
Acetyl-acceptor lysines are critical for
Tat's interactions with TAR, cyclin T1, and PCAF. A,
in vitro translated 35S-labeled wild-type
(Wt) and mutant Tat were incubated with synthetic
biotinylated TAR RNA (2 µg) or denatured TAR RNA (lane
2) that had been immobilized on streptavidin-agarose beads.
Beads were washed, resolved by SDS-PAGE, and analyzed by
autoradiography (bound (b)). A sample of the
35S-labeled Tat proteins was analyzed directly (input
(i)). B, HeLa cells were transfected with
Tat-FLAG-expressing plasmids as indicated. Extracts were subjected to
immunoprecipitation using anti-FLAG antibody, and immunoprecipitates
were resolved by SDS-PAGE followed by immunoblotting using anti-cyclin
T1 antibody (upper panel) or anti-FLAG antibody
(lower panel). C, NIH 3T3 cells were
co-transfected with 1 µg of pLTR-luc wild type, 0.1 µg of pRL-CMV,
and 0.5 µg of plasmids expressing wild-type or mutant Tat, in the
presence or absence of 0.5 µg of plasmid expressing human cyclin T1.
The relative luciferase activity was calculated following normalization
for Renilla luciferase activity expressed from the CMV
promoter present in the pRL-CMV internal control plasmid. The fold
HIV-1 Tat trans-activation was calculated relative to
transfections performed in the absence of Tat expression plasmids. A
representative experiment of three repeated transfections is shown.
D, the experiment was performed as described for
B except that immunoprecipitates resolved by SDS-PAGE were
immunoblotted with anti-PCAF antibody (upper
panel) or anti-FLAG antibody (lower
panel). WB, Western blot; IP,
immunoprecipitation.
-galactosidase activity was measured 24 h after transfection. As shown in Fig. 4, Tat
K28Q, Tat K28R, and Tat K50Q reduced Tat wild-type transcriptional
activity by 60, 40, and 70%, respectively. Tat K50R, Tat K29R, and Tat
K41A showed no trans-dominant effect. Taken together, these
experiments highlight the importance of cyclin T1 and PCAF in
Tat-mediated trans-activation of the HIV-1 LTR.

View larger version (9K):
[in a new window]
Fig. 4.
Tat acetyl-acceptor mutants show a
trans-dominant effect on Tat wild-type transcriptional
activity. Extracts of HeLa P4 cells, transfected with wild-type
(Wt) Tat alone or together with Tat mutants as indicated,
were assayed for
-galactosidase activity 24 h
post-transfection. A representative experiment of three repeated
transfections is shown.

View larger version (63K):
[in a new window]
Fig. 5.
Tat acetyl-acceptor mutants show an altered
subcellular localization. HeLa cells were transfected with the
indicated Tat-FLAG expression plasmids and stained with anti-FLAG
antibody followed by Texas Red-conjugated anti-mouse antibody.
wt, wild type.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B, that in turn activate the HIV-1 promoter (54-56). Tat also
plays an important role in reverse transcription of the viral RNA (1).
Thus, the K50R mutation within Tat may affect its nontranscriptional
activities and, consequently, virus replication. Consistent with this
hypothesis, only 7% of transfected cells showed both cytoplasmic and
nuclear localization of Tat K50R compared with 22% of Tat wild
type-transfected cells, suggesting a defect in its secretion. Taken
together, these results suggest that the transcriptional activity of
Tat is necessary but not sufficient to support virus replication.
![]()
ACKNOWLEDGEMENTS
) construct.
HIV-1-neutralizing serum was obtained through the NIH AIDS
Research and Reference Reagent Program from L. Vujcic.
![]()
FOOTNOTES
Supported by a Ministere de l'Education nationale, de la
Recherche et de la Technologie scholarship.
To whom correspondence should be addressed. Tel.:
33-4-99-61-99-32; Fax: 33-4-99-61-99-01; E-mail:
bmonsef@igh.cnrs.fr.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Harrich, D.,
Ulich, C.,
Garcia-Martinez, L. F.,
and Gaynor, R. B.
(1997)
EMBO J.
16,
1224-1235[CrossRef][Medline]
[Order article via Infotrieve]
2.
Frankel, A. D.,
and Pabo, C. O.
(1988)
Cell
55,
1189-1193[CrossRef][Medline]
[Order article via Infotrieve]
3.
Ensoli, B.,
Barillari, G.,
Salahuddin, S. Z.,
Gallo, R. C.,
and Wong-Staal, F.
(1990)
Nature
345,
84-86[CrossRef][Medline]
[Order article via Infotrieve]
4.
Albini, A.,
Ferrini, S.,
Benelli, R.,
Sforzini, S.,
Giunciuglio, D.,
Aluigi, M. G.,
Proudfoot, A. E.,
Alouani, S.,
Wells, T. N.,
Mariani, G.,
Rabin, R. L.,
Farber, J. M.,
and Noonan, D. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13153-13158 5.
Barillari, G.,
Gendelman, R.,
Gallo, R. C.,
and Ensoli, B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
7941-7945 6.
Gallo, R. C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
8324-8326 7.
Huang, L.,
Bosch, I.,
Hofmann, W.,
Sodroski, J.,
and Pardee, A. B.
(1998)
J. Virol.
72,
8952-8960 8.
Secchiero, P.,
Zella, D.,
Capitani, S.,
Gallo, R. C.,
and Zauli, G.
(1999)
J. Immunol.
162,
2427-2431 9.
Viscidi, R. P.,
Mayur, K.,
Lederman, H. M.,
and Frankel, A. D.
(1989)
Science
246,
1606-1608 10.
Zagury, D.,
Lachgar, A.,
Chams, V.,
Fall, L. S.,
Bernard, J.,
Zagury, J. F.,
Bizzini, B.,
Gringeri, A.,
Santagostino, E.,
Rappaport, J.,
Feldman, M.,
Burny, A.,
and Gallo, R. C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3851-3856 11.
Li, C. J.,
Friedman, D. J.,
Wang, C.,
Metelev, V.,
and Pardee, A. B.
(1995)
Science
268,
429-431 12.
Westendorp, M. O.,
Frank, R.,
Ochsenbauer, C.,
Stricker, K.,
Dhein, J.,
Walczak, H.,
Debatin, K. M.,
and Krammer, P. H.
(1995)
Nature
375,
497-500[CrossRef][Medline]
[Order article via Infotrieve]
13.
Xiao, H.,
Neuveut, C.,
Tiffany, H. L.,
Benkirane, M.,
Rich, E. A.,
Murphy, P. M.,
and Jeang, K. T.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11466-11471 14.
Berkhout, B.,
Silverman, R. H.,
and Jeang, K. T.
(1989)
Cell
59,
273-282[CrossRef][Medline]
[Order article via Infotrieve]
15.
Dingwall, C.,
Ernberg, I.,
Gait, M. J.,
Green, S. M.,
Heaphy, S.,
Karn, J.,
Lowe, A. D.,
Singh, M.,
Skinner, M. A.,
and Valerio, R.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
6925-6929 16.
Jones, K. A.,
and Peterlin, B. M.
(1994)
Annu. Rev. Biochem.
63,
717-743[CrossRef][Medline]
[Order article via Infotrieve]
17.
Roy, S.,
Delling, U.,
Chen, C. H.,
Rosen, C. A.,
and Sonenberg, N.
(1990)
Genes Dev.
4,
1365-1373 18.
Calnan, B. J.,
Biancalana, S.,
Hudson, D.,
and Frankel, A. D.
(1991)
Genes Dev.
5,
201-210 19.
Marciniak, R. A.,
Calnan, B. J.,
Frankel, A. D.,
and Sharp, P. A.
(1990)
Cell
63,
791-802[CrossRef][Medline]
[Order article via Infotrieve]
20.
Jeang, K. T.,
Xiao, H.,
and Rich, E. A.
(1999)
J. Biol. Chem.
274,
28837-28840 21.
Jones, K. A.
(1997)
Genes Dev.
11,
2593-2599 22.
Herrmann, C. H.,
and Rice, A. P.
(1993)
Virology
197,
601-608[CrossRef][Medline]
[Order article via Infotrieve]
23.
Herrmann, C. H.,
and Rice, A. P.
(1995)
J. Virol.
69,
1612-1620[Abstract]
24.
Gold, M. O.,
Yang, X.,
Herrmann, C. H.,
and Rice, A. P.
(1998)
J. Virol.
72,
4448-4453 25.
Hottiger, M. O.,
and Nabel, G. J.
(1998)
J. Virol.
72,
8252-8256 26.
Marzio, G.,
Tyagi, M.,
Gutierrez, M. I.,
and Giacca, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13519-13524 27.
Benkirane, M.,
Chun, R. F.,
Xiao, H.,
Ogryzko, V. V.,
Howard, B. H.,
Nakatani, Y.,
and Jeang, K. T.
(1998)
J. Biol. Chem.
273,
24898-24905 28.
Col, E.,
Caron, C.,
Seigneurin-Berny, D.,
Gracia, J.,
Favier, A.,
and Khochbin, S.
(2001)
J. Biol. Chem.
276,
28179-28184 29.
Zhu, Y.,
Pe'ery, T.,
Peng, J.,
Ramanathan, Y.,
Marshall, N.,
Marshall, T.,
Amendt, B.,
Mathews, M. B.,
and Price, D. H.
(1997)
Genes Dev.
11,
2622-2632 30.
Mancebo, H. S.,
Lee, G.,
Flygare, J.,
Tomassini, J.,
Luu, P.,
Zhu, Y.,
Peng, J.,
Blau, C.,
Hazuda, D.,
Price, D.,
and Flores, O.
(1997)
Genes Dev.
11,
2633-2644 31.
Garber, M. E.,
Wei, P.,
and Jones, K. A.
(1998)
Cold Spring Harbor Symp. Quant. Biol.
63,
371-380[CrossRef][Medline]
[Order article via Infotrieve]
32.
Wei, P.,
Garber, M. E.,
Fang, S. M.,
Fischer, W. H.,
and Jones, K. A.
(1998)
Cell
92,
451-462[CrossRef][Medline]
[Order article via Infotrieve]
33.
Zhou, Q.,
Chen, D.,
Pierstorff, E.,
and Luo, K.
(1998)
EMBO J.
17,
3681-3691[CrossRef][Medline]
[Order article via Infotrieve]
34.
Peng, J.,
Zhu, Y.,
Milton, J. T.,
and Price, D. H.
(1998)
Genes Dev.
12,
755-762 35.
Isel, C.,
and Karn, J.
(1999)
J. Mol. Biol.
290,
929-941[CrossRef][Medline]
[Order article via Infotrieve]
36.
Zhou, M.,
Halanski, M. A.,
Radonovich, M. F.,
Kashanchi, F.,
Peng, J.,
Price, D. H.,
and Brady, J. N.
(2000)
Mol. Cell. Biol.
20,
5077-5086 37.
Price, D. H.
(2000)
Mol. Cell. Biol.
20,
2629-2634 38.
Weissman, J. D.,
Brown, J. A.,
Howcroft, T. K.,
Hwang, J.,
Chawla, A.,
Roche, P. A.,
Schiltz, L.,
Nakatani, Y.,
and Singer, D. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11601-11606 39.
Creaven, M.,
Hans, F.,
Mutskov, V.,
Col, E.,
Caron, C.,
Dimitrov, S.,
and Khochbin, S.
(1999)
Biochemistry
38,
8826-8830[CrossRef][Medline]
[Order article via Infotrieve]
40.
Kiernan, R. E.,
Vanhulle, C.,
Schiltz, L.,
Adam, E.,
Xiao, H.,
Maudoux, F.,
Calomme, C.,
Burny, A.,
Nakatani, Y.,
Jeang, K. T.,
Benkirane, M.,
and Van Lint, C.
(1999)
EMBO J.
18,
6106-6118[CrossRef][Medline]
[Order article via Infotrieve]
41.
Ott, M.,
Schnolzer, M.,
Garnica, J.,
Fischle, W.,
Emiliani, S.,
Rackwitz, H. R.,
and Verdin, E.
(1999)
Curr. Biol.
9,
1489-1492[CrossRef][Medline]
[Order article via Infotrieve]
42.
Deng, L.,
de la Fuente, C., Fu, P.,
Wang, L.,
Donnelly, R.,
Wade, J. D.,
Lambert, P., Li, H.,
Lee, C. G.,
and Kashanchi, F.
(2000)
Virology
277,
278-295[CrossRef][Medline]
[Order article via Infotrieve]
43.
Adachi, A.,
Gendelman, H. E.,
Koenig, S.,
Folks, T.,
Willey, R.,
Rabson, A.,
and Martin, M. A.
(1986)
J. Virol.
59,
284-291 44.
Joshi, A.,
and Jeang, K. T.
(1993)
BioTechniques
14,
880[Medline]
[Order article via Infotrieve], 884-886
45.
Huang, L. M.,
Joshi, A.,
Willey, R.,
Orenstein, J.,
and Jeang, K. T.
(1994)
EMBO J.
13,
2886-2896[Medline]
[Order article via Infotrieve]
46.
Clavel, F.,
and Charneau, P.
(1994)
J. Virol.
68,
1179-1185 47.
Neuveut, C.,
and Jeang, K. T.
(1996)
J. Virol.
70,
5572-5581 48.
Cullen, B. R.,
Hauber, J.,
Campbell, K.,
Sodroski, J. G.,
Haseltine, W. A.,
and Rosen, C. A.
(1988)
J. Virol.
62,
2498-2501 49.
Stauber, R. H.,
and Pavlakis, G. N.
(1998)
Virology
252,
126-136[CrossRef][Medline]
[Order article via Infotrieve]
50.
Jeang, K. T.,
Berkhout, B.,
and Dropulic, B.
(1993)
J. Biol. Chem.
268,
24940-24949 51.
Verdin, E.,
Paras, P., Jr.,
and Van Lint, C.
(1993)
EMBO J.
12,
3249-3259[Medline]
[Order article via Infotrieve]
52.
El Kharroubi, A.,
Piras, G.,
Zensen, R.,
and Martin, M. A.
(1998)
Mol. Cell. Biol.
18,
2535-2544 53.
Ott, M.,
Emiliani, S.,
Van Lint, C.,
Herbein, G.,
Lovett, J.,
Chirmule, N.,
McCloskey, T.,
Pahwa, S.,
and Verdin, E.
(1997)
Science
275,
1481-1485 54.
Demarchi, F.,
d'Adda di Fagagna, F.,
Falaschi, A.,
and Giacca, M.
(1996)
J. Virol.
70,
4427-4437[Abstract]
55.
Demarchi, F.,
Gutierrez, M. I.,
and Giacca, M.
(1999)
J. Virol.
73,
7080-7086 56.
Manna, S. K.,
and Aggarwal, B. B.
(2000)
J. Immunol.
164,
5156-5166 57.
Cafaro, A.,
Caputo, A.,
Fracasso, C.,
Maggiorella, M. T.,
Goletti, D.,
Baroncelli, S.,
Pace, M.,
Sernicola, L.,
Koanga-Mogtomo, M. L.,
Betti, M.,
Borsetti, A.,
Belli, R.,
Akerblom, L.,
Corrias, F.,
Butto, S.,
Heeney, J.,
Verani, P.,
Titti, F.,
and Ensoli, B.
(1999)
Nat. Med.
5,
643-650[CrossRef][Medline]
[Order article via Infotrieve]
58.
Osterhaus, A. D.,
van Baalen, C. A.,
Gruters, R. A.,
Schutten, M.,
Siebelink, C. H.,
Hulskotte, E. G.,
Tijhaar, E. J.,
Randall, R. E.,
van Amerongen, G.,
Fleuchaus, A.,
Erfle, V.,
and Sutter, G.
(1999)
Vaccine
17,
2713-2714[CrossRef][Medline]
[Order article via Infotrieve]
59.
Cafaro, A.,
Caputo, A.,
Maggiorella, M. T.,
Baroncelli, S.,
Fracasso, C.,
Pace, M.,
Borsetti, A.,
Sernicola, L.,
Negri, D. R.,
Ten Haaft, P.,
Betti, M.,
Michelini, Z.,
Macchia, I.,
Fanales-Belasio, E.,
Belli, R.,
Corrias, F.,
Butto, S.,
Verani, P.,
Titti, F.,
and Ensoli, B.
(2000)
J. Med. Primatol.
29,
193-208[CrossRef][Medline]
[Order article via Infotrieve]
60.
Ensoli, B.,
and Cafaro, A.
(2000)
J. Biol. Regul. Homeost. Agents
14,
22-26[Medline]
[Order article via Infotrieve]
61.
Pauza, C. D.,
Trivedi, P.,
Wallace, M.,
Ruckwardt, T. J., Le,
Buanec, H., Lu, W.,
Bizzini, B.,
Burny, A.,
Zagury, D.,
and Gallo, R. C.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3515-3519
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Sharma, S. Awasthi, C. K. Harrod, E. F. Matlock, S. Khan, L. Xu, S. Chan, H. Yang, C. K. Thammavaram, R. A. Rasor, et al. The Werner Syndrome Helicase Is a Cofactor for HIV-1 Long Terminal Repeat Transactivation and Retroviral Replication J. Biol. Chem., April 20, 2007; 282(16): 12048 - 12057. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Berro, K. Kehn, C. de la Fuente, A. Pumfery, R. Adair, J. Wade, A. M. Colberg-Poley, J. Hiscott, and F. Kashanchi Acetylated Tat Regulates Human Immunodeficiency Virus Type 1 Splicing through Its Interaction with the Splicing Regulator p32. J. Virol., April 1, 2006; 80(7): 3189 - 3204. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ranjbar, R. Rajsbaum, and A. E. Goldfeld Transactivator of Transcription from HIV Type 1 Subtype E Selectively Inhibits TNF Gene Expression via Interference with Chromatin Remodeling of the TNF Locus J. Immunol., April 1, 2006; 176(7): 4182 - 4190. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Desfosses, M. Solis, Q. Sun, N. Grandvaux, C. Van Lint, A. Burny, A. Gatignol, M. A. Wainberg, R. Lin, and J. Hiscott Regulation of Human Immunodeficiency Virus Type 1 Gene Expression by Clade-Specific Tat Proteins J. Virol., July 15, 2005; 79(14): 9180 - 9191. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Xie, V. Calabro, M. A. Wainberg, and A. D. Frankel Selection of TAR RNA-Binding Chameleon Peptides by Using a Retroviral Replication System J. Virol., February 1, 2004; 78(3): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Apolloni, C. W. Hooker, J. Mak, and D. Harrich Human Immunodeficiency Virus Type 1 Protease Regulation of Tat Activity Is Essential for Efficient Reverse Transcription and Replication J. Virol., September 15, 2003; 77(18): 9912 - 9921. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||